Generic Co. Gets Horizon's Painkiller Patent Partly Axed

Law360 (December 1, 2020, 4:41 PM EST) -- Horizon was dealt a loss in its patent fight over the painkiller drug Duexis after a Delaware federal judge ruled that part of the drugmaker's patent is invalid and not infringed by Alkem Laboratories Ltd.'s planned generic version of the drug.

In a 64-page opinion Monday, U.S. District Judge Richard G. Andrews ruled that four claims in Horizon Medicines LLC's patent for Duexis were invalid for being obvious due to an earlier study known as Taha and other patent publications.

Horizon had argued that an ordinarily skilled artisan wouldn't have known what a "standard" dosage of ibuprofen meant in light of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!